vs
Side-by-side financial comparison of DMC Global Inc. (BOOM) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
DMC Global Inc. is the larger business by last-quarter revenue ($143.5M vs $86.8M, roughly 1.7× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -5.8%). DMC Global Inc. produced more free cash flow last quarter ($9.6M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -7.3%).
DMC Mining Services is a mining services contractor founded in 1980 operating in Canada, the United States, Chile, and Mongolia
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
BOOM vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $143.5M | $86.8M |
| Net Profit | $-11.2M | — |
| Gross Margin | 17.1% | 67.4% |
| Operating Margin | -7.8% | -84.7% |
| Net Margin | -7.8% | — |
| Revenue YoY | -5.8% | 17.7% |
| Net Profit YoY | -3871.6% | — |
| EPS (diluted) | $-0.60 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $143.5M | $86.8M | ||
| Q3 25 | $151.5M | $67.5M | ||
| Q2 25 | $155.5M | $60.0M | ||
| Q1 25 | $159.3M | $49.3M | ||
| Q4 24 | $152.4M | $73.7M | ||
| Q3 24 | $152.4M | $58.6M | ||
| Q2 24 | $171.2M | $31.1M | ||
| Q1 24 | $166.9M | $715.0K |
| Q4 25 | $-11.2M | — | ||
| Q3 25 | $-3.1M | $-91.3M | ||
| Q2 25 | $116.0K | $-111.7M | ||
| Q1 25 | $677.0K | $-116.2M | ||
| Q4 24 | $296.0K | — | ||
| Q3 24 | $-101.3M | $-83.5M | ||
| Q2 24 | $4.0M | $-97.1M | ||
| Q1 24 | $2.6M | $-113.0M |
| Q4 25 | 17.1% | 67.4% | ||
| Q3 25 | 21.7% | 43.0% | ||
| Q2 25 | 23.6% | 5.5% | ||
| Q1 25 | 25.9% | -0.8% | ||
| Q4 24 | 20.8% | 68.7% | ||
| Q3 24 | 19.8% | 46.2% | ||
| Q2 24 | 27.1% | -0.8% | ||
| Q1 24 | 25.4% | — |
| Q4 25 | -7.8% | -84.7% | ||
| Q3 25 | 0.4% | -140.7% | ||
| Q2 25 | 2.5% | -189.8% | ||
| Q1 25 | 4.1% | -245.8% | ||
| Q4 24 | -0.5% | -117.5% | ||
| Q3 24 | -97.7% | -152.1% | ||
| Q2 24 | 6.8% | -327.6% | ||
| Q1 24 | 4.0% | -16464.6% |
| Q4 25 | -7.8% | — | ||
| Q3 25 | -2.0% | -135.3% | ||
| Q2 25 | 0.1% | -186.2% | ||
| Q1 25 | 0.4% | -235.5% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | -66.5% | -142.7% | ||
| Q2 24 | 2.3% | -312.2% | ||
| Q1 24 | 1.5% | -15800.8% |
| Q4 25 | $-0.60 | — | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $-0.24 | $-0.33 | ||
| Q1 25 | $0.04 | $-0.36 | ||
| Q4 24 | $-0.18 | $-0.24 | ||
| Q3 24 | $-8.27 | $-0.28 | ||
| Q2 24 | $0.24 | $-0.34 | ||
| Q1 24 | $0.01 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.9M | $297.0M |
| Total DebtLower is stronger | $50.6M | — |
| Stockholders' EquityBook value | $242.1M | $698.6M |
| Total Assets | $635.8M | $913.2M |
| Debt / EquityLower = less leverage | 0.21× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.9M | $297.0M | ||
| Q3 25 | $26.4M | $300.8M | ||
| Q2 25 | $12.4M | $301.2M | ||
| Q1 25 | $14.7M | $359.7M | ||
| Q4 24 | $14.3M | $323.8M | ||
| Q3 24 | $14.5M | $397.5M | ||
| Q2 24 | $14.6M | $412.5M | ||
| Q1 24 | $20.4M | $356.2M |
| Q4 25 | $50.6M | — | ||
| Q3 25 | $56.5M | — | ||
| Q2 25 | $58.7M | — | ||
| Q1 25 | $72.4M | — | ||
| Q4 24 | $70.8M | — | ||
| Q3 24 | $74.2M | — | ||
| Q2 24 | $84.1M | — | ||
| Q1 24 | $88.0M | — |
| Q4 25 | $242.1M | $698.6M | ||
| Q3 25 | $253.0M | $702.3M | ||
| Q2 25 | $253.9M | $698.5M | ||
| Q1 25 | $253.9M | $767.9M | ||
| Q4 24 | $251.0M | $710.4M | ||
| Q3 24 | $256.5M | $773.5M | ||
| Q2 24 | $416.0M | $768.5M | ||
| Q1 24 | $409.9M | $680.0M |
| Q4 25 | $635.8M | $913.2M | ||
| Q3 25 | $644.1M | $904.9M | ||
| Q2 25 | $645.0M | $907.4M | ||
| Q1 25 | $670.6M | $966.7M | ||
| Q4 24 | $671.3M | $910.4M | ||
| Q3 24 | $702.0M | $991.1M | ||
| Q2 24 | $869.5M | $964.3M | ||
| Q1 24 | $860.0M | $869.8M |
| Q4 25 | 0.21× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.23× | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.29× | — | ||
| Q2 24 | 0.20× | — | ||
| Q1 24 | 0.21× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.2M | $-52.6M |
| Free Cash FlowOCF − Capex | $9.6M | $-61.9M |
| FCF MarginFCF / Revenue | 6.7% | -71.3% |
| Capex IntensityCapex / Revenue | 3.9% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $37.0M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.2M | $-52.6M | ||
| Q3 25 | $18.6M | $-78.7M | ||
| Q2 25 | $15.2M | $-67.4M | ||
| Q1 25 | $4.5M | $-103.7M | ||
| Q4 24 | $11.8M | $-73.3M | ||
| Q3 24 | $19.0M | $-59.0M | ||
| Q2 24 | $2.3M | $-98.4M | ||
| Q1 24 | $13.4M | $-122.3M |
| Q4 25 | $9.6M | $-61.9M | ||
| Q3 25 | $14.4M | $-89.5M | ||
| Q2 25 | $12.3M | $-74.9M | ||
| Q1 25 | $709.0K | $-109.9M | ||
| Q4 24 | $6.1M | $-77.5M | ||
| Q3 24 | $12.9M | $-61.3M | ||
| Q2 24 | $-204.0K | $-98.9M | ||
| Q1 24 | $10.5M | $-126.5M |
| Q4 25 | 6.7% | -71.3% | ||
| Q3 25 | 9.5% | -132.7% | ||
| Q2 25 | 7.9% | -124.9% | ||
| Q1 25 | 0.4% | -222.8% | ||
| Q4 24 | 4.0% | -105.1% | ||
| Q3 24 | 8.5% | -104.6% | ||
| Q2 24 | -0.1% | -317.9% | ||
| Q1 24 | 6.3% | -17685.3% |
| Q4 25 | 3.9% | 10.7% | ||
| Q3 25 | 2.8% | 16.1% | ||
| Q2 25 | 1.9% | 12.4% | ||
| Q1 25 | 2.4% | 12.6% | ||
| Q4 24 | 3.7% | 5.7% | ||
| Q3 24 | 4.0% | 3.9% | ||
| Q2 24 | 1.5% | 1.4% | ||
| Q1 24 | 1.8% | 583.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 131.43× | — | ||
| Q1 25 | 6.63× | — | ||
| Q4 24 | 39.90× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.58× | — | ||
| Q1 24 | 5.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BOOM
| Dyna Energetics Segment | $68.9M | 48% |
| Other | $57.0M | 40% |
| Nobel Clad Segment | $17.7M | 12% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
